Immunotherapy

Immunotherapy includes companies using the immune system to fight disease, especially cancer and autoimmune conditions. This can include checkpoint inhibitors, immune agonists, engineered immune cells, therapeutic vaccines, and other approaches that modify immune activity.

Why watch Immunotherapy

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Immunotherapy news

The latest feed items from companies currently grouped under Immunotherapy.

1. 01
   2026-11-06 21:00 EST

   BMYBristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

   Source: BMYBristol-Myers Squibb Company

2. 02
   2026-11-06 17:00 EST

   IMCRImmunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

   Source: Immunocore Holdings plc

3. 03
   2026-11-06 14:00 EST

   CADLCandel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

   Source: Candel Therapeutics

4. 04
   2026-11-06 14:00 EST

   IMCRImmunocore reports third quarter financial results and provides a business update

   Source: Immunocore Holdings plc

5. 05
   2026-11-05 21:06 EST

   CADLCandel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

   Source: Candel Therapeutics

6. 06
   2026-11-05 13:30 EST

   APVOAptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML

   Source: Aptevo Therapeutics

7. 07
   2026-11-05 12:45 EST

   INTSIntensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

   Source: Intensity Therapeutics

8. 08
   2026-11-04 21:05 EST

   LYELLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

   Source: Lyell Immunopharma

9. 09
   2026-11-04 14:02 EST

   LYELLyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission

   Source: Lyell Immunopharma

10. 10
    2026-11-04 14:01 EST

    LYELLyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma

    Source: Lyell Immunopharma

11. 11
    2026-11-04 14:00 EST

    SLSSELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

    Source: SELLAS Life Sciences Group, Inc.

12. 12
    2026-11-04 13:00 EST

    IBRXImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

    Source: ImmunityBio

13. 13
    2026-11-04 12:00 EST

    MDNAMedicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders

    Source: Medicenna Therapeutics Corp.

14. 14
    2026-11-03 21:30 EST

    XLOXilio Therapeutics to Present at the Stifel 2026 Healthcare Conference

    Source: Xilio Therapeutics

15. 15
    2026-11-03 14:00 EST

    BCTXBriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026

    Source: BriaCell

16. 16
    2026-11-03 12:00 EST

    RNACCartesian Therapeutics Announces New Employment Inducement Grant

    Source: Cartesian Therapeutics

17. 17
    2026-11-02 21:35 EST

    INKTMiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy

    Source: MiNK Therapeutics, Inc.

18. 18
    2026-11-02 21:05 EST

    CADLCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Source: Candel Therapeutics

19. 19
    2026-11-02 14:00 EST

    CMPXCompass Therapeutics to Participate in Upcoming November Investor Events

    Source: Compass Therapeutics

20. 20
    2026-11-02 14:00 EST

    ENLVEnlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response

    Source: Enlivex Therapeutics

Companies in Immunotherapy

68 companies tagged with Immunotherapy.

Frequently Asked Questions